A Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

4500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-04-30

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to evaluate if Danning Tablets are effective in alleviating dyspepsia in patients with any of the following digestive symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation.

The main questions it aims to answer are:

How effective are Danning Tablets for patients with indigestion symptoms? What are the impact factors (e.g. severity of conditions, demographic features, dose and length of treatment etc.) of the efficacy of Danning Tablets for indigestion patients?

Participants already taking Danning Tablets as part of their regular medical care for indigestion will take questionnaires by the end of two weeks and four weeks respectively from the start of their treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Preliminarily Evaluate the Efficacy of Domperidone in Adult Chinese Participants With Functional Dyspepsia

NCT03617016

Dyspepsia

COMPLETED PHASE4

International Clinical Study of Zhizhu Kuanzhong Capsule

NCT03825692

Functional Dyspepsia Postprandial Distress Syndrome

UNKNOWN PHASE4

The Efficacy and Safety of Qizhiweitong Granule on Patients With Functional Dyspepsia in a Multi-center Clinical Study

NCT02460601

Functional Dyspepsia

COMPLETED PHASE4

Study of Motilitone to Treat Functional Dyspepsia

NCT02365701

Dyspepsia

COMPLETED PHASE2

The Effect of Multiple Medications on the Incidence of Organic Dyspepsia

NCT05524675

Dyspepsia

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Indigestion Dyspepsia Bloating Loss of Appetite Reflux Acid Constipation Upper Abdominal Pain Functional Dyspepsia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with dyspepsia symptoms taking Danning Tablets

1. Patients between 18 and 75 years old;
2. Patients with at least one of the following symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation;
3. Patients already taking Danning Tablets as part of their regular medicine treatment for dyspepsia;
4. Patients agree to sign the informed consent form.

Danning Tablet

Intervention Type DRUG

Danning Tablet is the only exposure in this observational study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Danning Tablet

Danning Tablet is the only exposure in this observational study.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients between 18 and 75 years old
* Patients with at least one of the following symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation
* Patients already taking Danning Tablets as part of their regular medicine treatment for dyspepsia
* Patients agree to sign the informed consent form

Exclusion Criteria

* Past history or comorbidity of malignant tumor
* Comorbidity of severe systemic condition including cardiovascular, cerebrovascular, renal and hematopoietic system diseases
* Past history of abdominal surgery (post pancreatic surgery, post subtotal gastrectomy; incomplete intestinal obstruction) or mental illness, mobility difficulty (e.g. long-term bed ridden)
* Comorbidity of any unstable chronic or acute disease,which may impact the evaluation of treatment efficacy as determined by the research physician
* Pregnancy or breastfeeding
* Participation in other clinical trials within the past 3 months
* Other circumstances determined as ineligible by the research physician

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No